Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?

Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer

(2018) Gopa Iyer et al.   JOURNAL OF CLINICAL ONCOLOGY

Epigenetic silencing of miR-200b is associated with cisplatin resistance in bladder cancer

(2018) Tetsuya Shindo et al.   Oncotarget

Updated 2016 EAU Guidelines on Muscle-invasive and Metastatic Bladder Cancer

(2017) J. Alfred Witjes et al.   EUROPEAN UROLOGY

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

(2017) Roland Seiler et al.   EUROPEAN UROLOGY

Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification

(2017) Gottfrid Sjödahl et al.   JOURNAL OF PATHOLOGY

Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition

(2017) Jane Goodall et al.   Cancer Discovery

Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy

(2017) Bernhard Kiss et al.   Scientific Reports

Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer

(2017) K. M. Patel et al.   Scientific Reports

ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy

(2016) Floris H. Groenendijk et al.   EUROPEAN UROLOGY

A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer

(2016) David J. McConkey et al.   EUROPEAN UROLOGY

Final Pathological Stage after Neoadjuvant Chemotherapy and Radical Cystectomy for Bladder Cancer—Does pT0 Predict Better Survival than pTa/Tis/T1?

(2016) Homayoun Zargar et al.   JOURNAL OF UROLOGY

The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder

(2016) Alexander S. Baras et al.   OncoImmunology

Clinical Validation of Chemotherapy Response BiomarkerERCC2in Muscle-Invasive Urothelial Bladder Carcinoma

(2016) David Liu et al.   JAMA Oncology

Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease

(2015) Eleonor Olsson et al.   EMBO Molecular Medicine

Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer

(2015) Homayoun Zargar et al.   EUROPEAN UROLOGY

Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer

(2015) Elizabeth R. Plimack et al.   EUROPEAN UROLOGY

Do amount of variant differentiation and mitotic rate in bladder cancer change with neoadjuvant chemotherapy?

(2015) Helen M. Shen et al.   HUMAN PATHOLOGY

Emmprin Expression Predicts Response and Survival following Cisplatin Containing Chemotherapy for Bladder Cancer: A Validation Study

(2015) Tammer Hemdan et al.   JOURNAL OF UROLOGY

Bcl-2 predicts response to neoadjuvant chemotherapy and is overexpressed in lymph node metastases of urothelial cancer of the bladder

(2015) Bernhard Kiss et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Identification of proteins responsible for adriamycin resistance in breast cancer cells using proteomics analysis

(2015) Zhipeng Wang et al.   Scientific Reports

DO MIXED HISTOLOGICAL FEATURES AFFECT SURVIVAL BENEFIT FROM NEOADJUVANT PLATINUM-BASED COMBINATION CHEMOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED BLADDER CANCER?

(2015) Emil Scosyrev et al.   BJU INTERNATIONAL

Identification and Validation of Protein Biomarkers of Response to Neoadjuvant Platinum Chemotherapy in Muscle Invasive Urothelial Carcinoma

(2015) Alexander S. Baras et al.   PLoS One

Tumor Regression Grade of Urothelial Bladder Cancer After Neoadjuvant Chemotherapy

(2014) Achim Fleischmann et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy

(2014) Woonyoung Choi et al.   CANCER CELL

Cisplatin in cancer therapy: Molecular mechanisms of action

(2014) Shaloam Dasari et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Prevention of Cisplatin-Induced Hearing Loss by Intratympanic Dexamethasone

(2014) Tal Marshak et al.   OTOLARYNGOLOGY-HEAD AND NECK SURGERY

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

(2014) J. S. Damrauer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma

(2014) E. M. Van Allen et al.   Cancer Discovery

Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy

(2013) Stephen H. Culp et al.   JOURNAL OF UROLOGY

A Molecular Taxonomy for Urothelial Carcinoma

(2012) G. Sjodahl et al.   CLINICAL CANCER RESEARCH

Genome Sequencing Identifies a Basis for Everolimus Sensitivity

(2012) G. Iyer et al.   SCIENCE

Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer

(2011) Robert Rosenblatt et al.   EUROPEAN UROLOGY

Kuhn's Paradigms: Are Those Closest to Treating Bladder Cancer the Last to Appreciate the Paradigm Shift?

(2011) Dean F. Bajorin et al.   JOURNAL OF CLINICAL ONCOLOGY

International Phase III Trial Assessing Neoadjuvant Cisplatin, Methotrexate, and Vinblastine Chemotherapy for Muscle-Invasive Bladder Cancer: Long-Term Results of the BA06 30894 Trial

(2011)   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant Systemic Therapy or Early Cystectomy? Single-center Analysis of Outcomes After Therapy for Patients With Clinically Localized Micropapillary Urothelial Carcinoma of the Bladder

(2011) Islam A. Ghoneim et al.   UROLOGY

Mechanisms of Cisplatin Nephrotoxicity

(2010) Ronald P. Miller et al.   Toxins

The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1

(2008) Philip A. Gregory et al.   NATURE CELL BIOLOGY